- Home
- PIII vs LSTA Comparison
PIII vs LSTA Comparison
Compare PIII & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | LSTA |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | 360 | N/A |
| Industry | Medical/Nursing Services | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 16.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | PIII | LSTA |
|---|---|---|
| Price | $2.94 | $5.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.25 | $15.00 |
| AVG Volume (30 Days) | ★ 103.5K | 57.9K |
| Earning Date | 03-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.15 | $1.81 |
| 52 Week High | $11.30 | $5.07 |
Technical Indicators
Market Signals| Indicator | PIII | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 68.76 |
| Support Level | $2.35 | $2.31 |
| Resistance Level | $3.99 | $5.07 |
| Average True Range (ATR) | 0.49 | 0.03 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 47.72 | 93.62 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.